Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aromatase and gynecomastia.

G D Braunstein1

  • 1Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California 90048, USA.

Endocrine-Related Cancer
|March 24, 2000
PubMed
Summary

Gynecomastia results from an estrogen-androgen imbalance, often linked to increased aromatase activity. Further research into potent aromatase inhibitors is needed for effective gynecomastia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo.

Oncology letters·2012
Same author

Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.

British journal of cancer·2008
Same author

Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.

Rheumatology (Oxford, England)·2008
Same author

A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

The Journal of clinical endocrinology and metabolism·2003
Same author

Treatment of gynecomastia.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma.

Thyroid : official journal of the American Thyroid Association·2001

Area of Science:

  • Endocrinology
  • Oncology
  • Reproductive Medicine

Background:

  • Gynecomastia arises from an imbalance in estrogen and androgen activity within breast tissue.
  • Increased aromatization of androgens to estrogens is a key factor in gynecomastia pathogenesis.
  • Associated conditions include obesity, aging, puberty, liver disease, and certain neoplasms.

Purpose of the Study:

  • To review the role of aromatase in gynecomastia.
  • To evaluate the efficacy of current aromatase inhibitors.
  • To highlight the need for research on newer aromatase inhibitors.

Main Methods:

  • Literature review of gynecomastia pathogenesis and treatment.
  • Analysis of studies involving aromatase inhibition therapy.
  • Examination of clinical data on delta1-testolactone use.

Main Results:

  • Aromatase excess syndrome can cause significant gynecomastia.
  • Delta1-testolactone partially reduces breast glandular tissue size.
  • Limited data exists on the effectiveness of newer, potent aromatase inhibitors.

Conclusions:

  • Aromatase inhibition is a potential therapeutic strategy for gynecomastia.
  • Current treatments with delta1-testolactone show limited efficacy.
  • Further clinical studies on advanced aromatase inhibitors are warranted.

Related Experiment Videos